Trial Profile
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Colorectal cancer; Malignant melanoma; Ovarian cancer; Renal cell carcinoma; Sarcoma; Solid tumours
- Focus Adverse reactions
- 30 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 30 Dec 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 03 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.